Sanofi-Aventis To Increase S. Korea Investment By 20 Percent A Year
This article was originally published in PharmAsia News
The French drug maker Sanofi-Aventis said it plans to increase its investments in South Korea by 20 percent a year to beef up its clinical research in the country. The head of Sanofi-Aventis Korea said the firm also is investigating opportunities for joint projects with South Korean companies. He said the joint efforts would be primarily in new-drug development, marketing and promotion. Sanofi-Aventis spent nearly $14 million on about 50 different clinical studies in South Korea in 2007. (Click here for more
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.